The device treats lymphedema, a debilitating condition, often seen as a secondary consequence of surgery, particularly mastectomy. Our company has developed a proprietary, IP protected, Low Level Laser Therapy device (LLLT) that has achieved considerable market penetration and consumer satisfaction, and is now selling well in a number of international markets.
The clinically validated device has gained European Union and United States Food and Drug Administration (FDA) approvals/clearance and is the ONLY laser device cleared by the FDA for lymphedema treatment. Additionally, the device has been approved for the treatment of muscular-skeletal pain in both European and Australian jurisdictions with pending authorization in China and Korea. Use for veterinary indications is also approved in the US, Japan and Australia.
The company has now reached a stage of development where the founders believe the local and international growth potential is best fulfilled by seeking a strategic partner to fully capitalize on the undoubted global opportunity. The company has generated a solid platform of business and is now poised for rapid international growth. There is potential to establish positions in other key therapy areas, such as wound healing, based on clinical evidence. Manufacture is scalable to meet global market need and is currently secured with a US, European and Australian regulatory compliant manufacturer.
The company has established a well respected and engaged panel of leaders and collaborators in lymphedema and other indications and consequently holds strong relationships with distributors in the US, UK, Japan, Korea, Philippines and China. Sales have also been made in Turkey, India and South America although distributors have not been appointed. Contact for more information on this medical device manufacturing business for sale.